Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Human Resources Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,961 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 3,587 · Balance 25,961 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 24,025 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 1,936 · Balance 24,025 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. F3: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
F3: 21,985 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 913 | $116.72 | $106,566.46 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,737 F5 · kind: Sale of 913 shares of common stock issued upon vesting of 1,735 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (822) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 425 | $116.76 | $49,623.04 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,915 F3 · kind: Sale of 425 shares of common stock issued upon vesting of 1,215 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (790) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.2819. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:13 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 35,035 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023374 · doc4a.xml · derivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,035 Underlying: Common Stock · 35,035 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 605 | $113.86 | $68,886.21 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,125 F1 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.81 to $116.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 23:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $90.73 | $204,777.61 |
DisclosureSEC source: 0001209191-20-058541 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,580 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $91.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 20:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 987 | $95.26 | $94,021.62 |
DisclosureSEC source: 0001209191-20-053998 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,549 F1 · kind: Sale of 987 shares of common stock issued upon vesting of 1,875 restricted stock units on October 2, 2020 to cover payroll and withholding taxes, with the balance of the shares (888) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $118.91 | $268,382.80 |
DisclosureSEC source: 0001209191-20-045747 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,661 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.21 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,934 | $99.46 | $192,363.57 |
DisclosureSEC source: 0001209191-20-026065 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,631 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 247 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 913 | $103.26 | $94,276.20 |
DisclosureSEC source: 0001209191-20-008487 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: Sale of 913 shares of common stock issued upon vesting of 1,735 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (822) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 4,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007676 · doc4.xml · derivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,860 Underlying: Common Stock · 4,860 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 30,674 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007676 · doc4.xml · derivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,674 Underlying: Common Stock · 30,674 shares Expires 2030-02-06 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 605 | $103.17 | $62,417.31 |
DisclosureSEC source: 0001209191-20-007676 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,821 F1 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.08 to $104.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 22:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 987 | $88.56 | $87,408.72 |
DisclosureSEC source: 0001209191-19-052596 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,276 F1 · kind: Sale of 987 shares of common stock issued upon vesting of 1,875 restricted stock units on October 2, 2019 to cover payroll and withholding taxes, with the balance of the shares (888) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · balance_after: Includes a total of 472 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan. 287 shares were purchased on February 28, 2019 and 185 shares were purchased on August 30, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.